Federico Longo

6PUBLICATIONS
85CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Gene expression (incl. microarray and other genome-wide approaches)Molecular targetsApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|May 19, 2025
A Phase II Study of Perioperative Avelumab plus Chemotherapy for Patients with Resectable Gastric Cancer or Gastroesophageal Junction Cancer - The MONEO Study.

Maria Alsina, Guillermo Villacampa, Carlos de Andrea

|Jul 18, 2024
SEOM-GEMCAD-TTD clinical guideline for the diagnosis and treatment of gastric cancer (2023).

Fernando Rivera, Federico Longo, Marta Martín Richard

|May 06, 2024
Phase II Study to Determine the Antitumor Activity and Safety of Simlukafusp Alfa (FAP-IL2v) Combined with Atezolizumab in Esophageal Cancer.

Hans Prenen, Sanjeev Deva, Bhumsuk Keam

|Mar 29, 2023
Impact of the COVID-19 Pandemic on Cancer Diagnosis in Madrid (Spain) Based on the RTMAD Tumor Registry (2019-2021).

Gregorio Garrido-Cantero, Federico Longo, Javier Hernández-González

|Oct 03, 2022
Dose-escalated neoadjuvant chemoradiotherapy for locally advanced oesophageal or oesophagogastric junctional adenocarcinoma.

Victor Duque-Santana, Fernando López-Campos, Margarita Martin

|Oct 15, 2020
Intratumoral nanoplexed poly I:C BO-112 in combination with systemic anti-PD-1 for patients with anti-PD-1-refractory tumors.

Iván Márquez-Rodas, Federico Longo, Maria E Rodriguez-Ruiz

Pageof 1

Frequent Collaborators

3 joint publications

Mariano Ponz-Sarvise

2 joint publications

Maria Alsina

1 joint publications

Iván Márquez-Rodas

1 joint publications

Maria E Rodriguez-Ruiz